An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

RIN-PH-202 [NCT02633293]

This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 75 clinical trial centers. The study will continue until 2 years after the last subject is enrolled at any study site or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).


Drug: Inhaled Treprostinil

Primary Investigator: Engel

Drug/Device Information
To provide or continue to provide inhaled treprostinil for eligible subjects who participated in the RIN-PH-201 study
Treprostinil is a chemically stable tricyclic analogue of prostacyclin
Treprostinil for inhalation (Tyvaso) is approved in the United States for the treatment of PAH (WHO Group I)
All subjects will receive inhaled treprostinil during this open-label study
United Therapeutics Corp.